T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on ...

A cluster of recent studies has sharpened the scientific picture of how T cells switch on, tracking the molecular signals ...

The activation and regulation of T cells are fundamental to immune homeostasis and effective defence mechanisms. Ubiquitin ligases, such as c-Cbl and Cbl-b, serve as pivotal regulators by targeting ...

The orchestration of T cell activation is central to immune defence and self-tolerance. Recent advances have revealed that T cells integrate signals from their antigen receptors alongside a network of ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...

Researchers at the Kennedy Institute of Rheumatology have found that physically resisting the formation of an immunological synapse actually promotes a stronger immune response. The findings could ...

Immunotherapy has revolutionized the way physicians treat patients. Previously, chemotherapy was the standard-of-care with the goal to eliminate tumor cells by dysregulating their ability to ...

LabGenius Therapeutics will present preclinical data for LGTX-101, its AI-designed Nectin-4 x CD3 T-cell engager, at AACR 2026 in San Diego.

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study. This is an ASCO Meeting Abstract ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...